第一医药(600833) - 2025 Q2 - 季度业绩预告

Shanghai No. 1 Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast Current Period Performance Forecast The company forecasts a significant year-on-year decrease in H1 2025 net profit attributable to shareholders due to prior year non-recurring gains, while core business net profit is projected to grow H1 2025 Performance Forecast | Indicator | H1 2025 Estimated (Ten Thousand RMB) | Year-on-Year Change | | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | 1,260 to 1,580 | ↓ 87.83% to 90.29% | | Net Profit Excluding Non-Recurring Gains/Losses | 800 to 1,000 | ↑ 10.59% to 38.24% | - This performance forecast data is a preliminary estimate by the company's finance department and has not been audited by a certified public accountant[4][5] Prior Period Performance Review The H1 2024 review highlights a large disparity between reported net profit and net profit excluding non-recurring items, setting a high comparison base for the current period H1 2024 Financial Data | Indicator | H1 2024 Amount | | :--- | :--- | | Total Profit | 17,059.20 Ten Thousand RMB | | Net Profit Attributable to Parent Company Shareholders | 12,978.91 Ten Thousand RMB | | Net Profit Excluding Non-Recurring Gains/Losses | 723.37 Ten Thousand RMB | | Earnings Per Share | 0.5818 RMB | Core Reasons for Performance Change The substantial year-on-year decline in net profit attributable to parent company shareholders is primarily due to a large, one-time housing expropriation compensation in the prior period - The primary reason for the decrease in net profit attributable to parent company shareholders is the one-time housing expropriation compensation in the prior period, resulting in a higher comparison base[7] Risk Warning The company states this performance forecast is a preliminary, unaudited estimate by the finance department, with final data potentially differing, but no other major uncertainties are identified - This performance forecast is a preliminary calculation by the company's finance department and has not been audited by a certified public accountant, thus it contains uncertainties[8] Other Explanations The company reiterates that the forecast data is preliminary, and final accurate financial data will be based on the officially disclosed 2025 semi-annual report, advising investor caution - Final financial data will be subject to the company's officially disclosed 2025 semi-annual report; investors are advised to be aware of investment risks[9]